AstriVax Therapeutics

AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on vaccine technology developed at the Rega Institute. AstriVax is committed to addressing real-world challenges in vaccinology by building a first-in-class Plug & Play vaccine platform with a patented DNA-based technology that launches self-amplifying live attenuated viruses. Their versatile technology can be used to develop a wide range of vaccines to prevent and treat infectious diseases. The company aims to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens. The Belgium-based startup recently received a €3.00M grant investment on 12 December 2023, with the investment coming from Agentschap Innoveren & Ondernemen. This investment will likely enable AstriVax to further advance their groundbreaking vaccine platform and potentially bring innovative vaccine solutions to market. With its promising technology and strategic partnerships, AstriVax is positioned to make significant contributions to the field of vaccinology.